Persistence of Candida spp. in patients with inflammatory diseases of the respiratory and gastrointestinal tracts: analysis of laboratory studies in Kharkiv Region, Ukraine (2019–2021)

H. M. Bolshakova; V. V. Minukhin; I. V. Zhuravlova; O. V. Golubka; T. V. Chastii; I. Y. Kuchma; T. V. Savinova; Y. V. Shevchenko

doi:10.15421/0225068

H. M. Bolshakova Kharkiv Polytechnic Institute
V. V. Minukhin I. Mechnikov Institute of Microbiology and Immunology National Academy of Medical Sciences of Ukraine
I. V. Zhuravlova The Municipal Non-Profit Enterprise “City Children's Clinical Hospital No. 24” of the Kharkiv City Council
O. V. Golubka Kharkiv Polytechnic Institute
T. V. Chastii Kharkiv Polytechnic Institute
I. Y. Kuchma Kharkiv Polytechnic Institute
T. V. Savinova Regional Children's Infectious Diseases Hospital
Y. V. Shevchenko Kharkiv Polytechnic Institute

Keywords: Candida albicans, Candida non-albicans, invasive candidiasis, inflammatory conditions, intestinal dysbiosis, respiratory tract.

Abstract

Invasive mycoses are becoming an increasingly serious threat in healthcare due to their continuous spread, the ability of pathogens to develop resistance to antifungal drugs, and the limited availability of new effective therapeutic agents for the treatment of fungal infections. Today, the most common causative agents of systemic mycoses remain fungi of the genus Candida , specifically C . albicans . Over the past decades, the epidemiological picture of candidiasis has gradually changed due to the increasing prevalence of C . glabrata and C . parapsilosis in mycotic pathology. The authors investigated the prevalence and species spectrum of Candida spp. as potential causative agents of candidiasis among subjects with inflammatory conditions of the respiratory and gastro intestinal tracts in Kharkiv region (Ukraine) during the period 2019–2021. The obtained results indicate a rising persistence of Candida spp. in the observed groups, increasing from 4.3% in 2019 and 4.7% in 2020 to 8.3% in 2021, with C . albicans identified as the predominant species, accounting for 82.8% of cases. Among the non- albicans group, C . krusei predominated (6.9%), while other Candida species were isolated significantly less frequently: C. glabrata , C. tropicalis , and C. kefyr were found in 4.3%, 3.4%, and 2.6% of cases, respectively. The susceptibility profile of isolated strains to itraconazole, fluconazole, and voriconazole was examined. Cand i da non- albicans strains exhibited increased resistance to itraconazole (42.8%) and voriconazole (57.2%), whereas C. albicans isolates demonstrated higher levels of fluconazole resistance (69.4%). The analysis of the obtained results suggests a further increase in infectious complications caused by fungi of the genus Candida among p a tients with inflammatory processes of the respiratory and gastrointestinal tracts, which may require mandatory laboratory control of mycotic infections and adjustments in therapeutic treatment to prevent invasive candidiasis.

References

Arendrup, M. C., Arikan-Akdagli, S., Jørgensen, K. M., Barac, A., Steinmann, J., Toscano, C., Arsenijevic, V. A., Sartor, A., Lass-Flörl, C., Hamprecht, A., Matos, T., Rogers, B. R. S., Quiles, I., Buil, J., Özenci, V., Krause, R., Bassetti, M., Loughlin, L., Denis, B., Grancini, A., White, P. L., Lagrou, K., Willinger, B., Rautemaa-Richardson, R., Hamal, P., Ener, B., Unalan-Altintop, T., Evren, E., Hilmioglu-Polat, S., Oz, Y., Ozyurt, O. K., Aydin, F., Růžička, F., Meijer, E. F. J., Gangneux, J. P., Lockhart, D. E. A., Khanna, N., Logan, C., Scharmann, U., Desoubeaux, G., Roilides, E., Talento, A. F., van Dijk, K., Koehler, P., Salmanton-García, J., Cornely, O. A., & Hoenigl, M. (2023). European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: results from the ECMM Candida III study. The Journal of Infection, 87(5), 428–437.

Bacher, P., Hohnstein, T., Beerbaum, E., Röcker, M., Blango, M. G., Kaufmann, S., Röhmel, J., Eschenhagen, P., Grehn, C., Seidel, K., Rickerts, V., Lozza, L., Stervbo, U., Nienen, M., Babel, N., Milleck, J., Assenmacher, M., Cornely, O. A., Ziegler, M., Wisplinghoff, H., Heine, G., Worm, M., Siegmund, B., Maul, J., Creutz, P., Tabeling, C., Ruwwe-Glösenkamp, C., Sander, L. E., Knosalla, C., Brunke, S., Hube, B., Kniemeyer, O., Brakhage, A. A., Schwarz, C., & Scheffold, A. (2019). Human anti-fungal Th17 immunity and pathology rely on cross-reactivity against Candida albicans. Cell, 176(6), 1340–1355.

Beardsley, J., Kim, H. Y., Dao, A., Kidd, S., Alastruey-Izquierdo, A., Sorrell, T. C., Tacconelli, E., Chakrabarti, A., Harrison, T. S., Bongomin, F., Gigante, V., Galas, M., Siswanto, S., Dagne, D. A., Roitberg, F., Sati, H., Morrissey, C. O., & Alffenaar, J. W. (2024). Candida glabrata (Nakaseomyces glabrata): A systematic review of clinical and microbiological data from 2011 to 2021 to inform the World Health Organization Fungal priority pathogens list. Medical Mycology, 62(6), myae041.

Díaz-García, J., Machado, M., Alcalá, L., Reigadas, E., Pérez-Ayala, A., Gómez-García de la Pedrosa, E., Gónzalez-Romo, F., Cuétara, M. S., García-Esteban, C., Quiles-Melero, I., Zurita, N. D., Muñoz-Algarra, M., Durán-Valle, M. T., Sánchez-García, A., Muñoz, P., Escribano, P., Guinea, J., & CANDIMAD study group. (2023). Trends in antifungal resistance in Candida from a multicenter study conducted in Madrid (CANDIMAD study): Fluconazole-resistant C. parapsilosis spreading has gained traction in 2022. Antimicrobial Agents and Chemotherapy, 67(11), e00986-23.

Erami, M., Raiesi, O., Momen-Heravi, M., Getso, M. I., Fakhrehi, M., Mehri, N., Yarahmadi, M., Amiri, S., Raissi, V., & Hashemi, S. J. (2022). Clinical impact of Candida respiratory tract colonization and acute lung infections in critically ill patients with COVID-19 pneumonia. Microbial Pathogenesis, 166, 105520.

Froidefond, M., Sevestre, J., Chaudet, H., & Ranque, S. (2023). COVID-19 Is a confounder of increased Candida airway colonisation. Pathogens, 12(3), 463.

Jackson, D., Coke, L., Fernandez, K., & Brister, K. (2023). Invasive Candida pneumonia, in association with Candida esophagitis and gastritis, in a presumably immunocompetent patient. Autopsy and Case Reports, 13, e2023443.

Kakde, Y., Shah, D., Acharya, S., Shukla, S., & Kumar, S. (2023). Pulmonary candidiasis in an immunocompetent patient. Journal of Clinical and Diagnostic Research, 17(4), 1–3.

Kidd, S. E., Abdolrasouli, A., & Hagen, F. (2023). Fungal nomenclature: Managing change is the name of the game. Open forum infectious diseases, 10(1), ofac559.

Kirchner, F. R., Littringer, K., Altmeier, S., Tran, V. D. T., Schönherr, F., Lemberg, C., Pagni, M., Sanglard, D., Joller, N., & Leibund Gut-Landmann, S. (2019). Persistence of Candida albicans in the oral mucosa induces a curbed inflammatory host response that is independent of immunosuppression. Frontiers in Immunology, 10, 330.

Kohlenberg, A., Monnet, D. L., Plachouras, D., Candida auris survey collaborative group, & Candida auris survey collaborative group includes the following national experts (2022). Increasing number of cases and outbreaks caused by Candida auris in the EU/EEA, 2020 to 2021. Eurosurveillance, 27(46), 2200846.

Kovalenko, N. I., Zamazii, T. M., & Novikova, I. V. (2020). Study of the prevalence and resistance to antimycotics of Candida fungi in infectious diseases of the upper and lower respiratory tract. Actual Infectology, 8(5–6), 25–28.

Kurilovich, E., & Geva-Zatorsky, N. (2025). Effects of bacteriophages on gut microbiome functionality. Gut Microbes, 17(1), 2481178.

Kusakabe, T., Lin, W. Y., Cheong, J. G., Singh, G., & Iliev, I. D. (2023). Fungal microbiota sustains lasting immune activation of neutrophils and their progenitors in severe COVID-19. Nature Immunology, 24(11), 1879–1889.

Lamoth, F., Lewis, R. E., & Kontoyiannis, D. P. (2022). Investigational antifungal agents for invasive mycoses: A clinical perspective. Clinical Infectious Diseases, 75(3), 534–544.

Lone, S. A., & Ahmad, A. (2019). Candida auris – the growing menace to global health. Mycoses, 62(8), 620–637.

Marfil-Sánchez, A., Zhang, L., Alonso-Pernas, P., Mirhakkak, M., Mueller, M., Seelbinder, B., Ni, Y., Santhanam, R., Busch, A., Beemelmanns, C., Ermolaeva, M., Bauer, M., & Panagiotou, G. (2021). An integrative understanding of the large metabolic shifts induced by antibiotics in critical illness. Gut Microbes, 13(1), 1993598.

Mesquida, A., Machado, M., Dávila-Cherres, L., Vicente, T., Sánchez-Carrillo, C., Alcalá, L., Reigadas, E., Muñoz, P., Guinea, J., Escribano, P. (2023). The gastrointestinal tract is pinpointed as a reservoir of Candida albicans, Candida parapsilosis, and Candida tropicalis genotypes found in blood and intra-abdominal samples. Journal of Fungi, 9(7), 732.

Mogilnicka, I., & Ufnal, M. (2019). Gut mycobiota and fungal metabolites in human homeostasis. Current Drug Targets, 20(2), 232–240.

Ning, Y., Xiao, M., Perlin, D. S., Zhao, Y., Lu, M., Li, Y., Luo, Z., Dai, R., Li, S., Xu, J., Liu, L., He, H., Liu, Y., Li F., Guo, Y., Chen, Z., Xu, Y., Sun, T., & Zhang, L. (2023). Decreased echinocandin susceptibility in Candida parapsilosis causing candidemia and emergence of a pan-echinocandin resistant case in China. Emerging Microbes and Infections, 12(1), e2153086.

Paiva, J. A., & Pereira, J. M. (2023). Treatment of invasive candidiasis in the era of Candida resistance. Current Opinion in Critical Care, 29(5), 457–462.

Patnaik, S., Durairajan, S. S. K., Singh, A. K., Krishnamoorthi, S., Iyaswamy, A., Mandavi, S. P., Jeewon, R., & Williams, L. L. (2024). Role of Candida species in pathogenesis, immune regulation, and prognostic tools for managing ulcerative colitis and Crohn's disease. World Journal of Gastroenterology, 30(48), 5212–5220.

Plachouras, D., Lötsch, F., Kohlenberg A. & Monnet, D. L. (2020). Candida auris: Epidemiological situation, laboratory capacity and preparedness in the European Union and European Economic Area, January 2018 to May 2019. Eurosurveillance, 25(12), 2000240.

Routsi, C., Meletiadis, J., Charitidou, E., Gkoufa, A., Kokkoris, S., Karageorgiou, S., Giannopoulos, C., Koulenti, D., Andrikogiannopoulos, P., Perivolioti, E., Argyropoulou, A., Vasileiadis, I., Vrioni, G., & Paramythiotou, E. (2022). Epidemiology of candidemia and fluconazole resistance in an ICU before and during the COVID-19 pandemic era. Antibiotics, 11(6), 771.

Tóth, R., Nosek, J., Mora-Montes, H. M., Gabaldon, T., Bliss, J. M., Nosanchuk, J. D., Turner, S. A., Butler, G.,Vágvölgyi, C., & Gácser, A. (2019). Candida parapsilosis: From genes to the bedside. Clinical Microbiology Reviews, 32(2), 1–38.

Wang, L. L., Huang, S. J., Zhao, J. T., Liu, J. Y., & Xiang, M. J. (2024). Regulatory role of Mss11 in Candida glabrata virulence: Adhesion and biofilm formation. Frontiers in Cellular and Infection Microbiology, 13, 1321094.

Zeise, K. D., Falkowski, N. R., Stark, K. G., Brown, C. A., & Huffnagle, G. B. (2024). Profiling inflammatory outcomes of Candida albicans colonization and food allergy induction in the murine glandular stomach. mBio, 15(11), e0211324.

Zhai, B., Ola, M., Rolling, T., Tosini, N. L., Joshowitz, S., Littmann, E. R., Amoretti, L. A., Fontana, E., Wright, R. J., Miranda, E., Veelken, C. A., Morjaria, S. M., Peled, J. U., van den Brink, M. R. M., Babady, N. E., Butler, G., Taur, Y., & Hohl, T. M. (2020). High-resolution mycobiota analysis reveals dynamic intestinal translocation preceding invasive candidiasis. Nature Medicine, 26(1), 59–64.

Zhao, M., Chu, J., Feng, S., Guo, C., Xue, B., He, K., & Li, L. (2023). Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: A review. Biomedicine and Pharmacotherapy, 164, 114985.